New Drug Treatment Extends Lives of men with prostate cancer

The survival benefit observed in this study is particularly noteworthy because it has been observed in more advanced cases of prostate cancer, said Flaig. Further studies are underway to examine the advantage of using acetate Abiraterone earlier in the disease process, where it can be even more effective. University of Colorado Hospital is the leading academic medical center in the Rocky Mountain region. It ‘finished in the top 10 academic medical centers by the University HealthSystem Consortium in the United States and is ranked as the best hospital in the Denver metropolitan area and one of the best in the country by USNews & World Report. Doctors Hospital affiliated to the University of Colorado School of Medicine, part of the University of Colorado system. Based on the Anschutz Medical Campus wide Aurora, Colorado, the hospital is crucial for a country only true health city , where patient care, research and education converge to determine the future delivery of health care. For news and additional information, please visit the University of Colorado at Denver writing.

[The] data show at least one area where antibiotics are commonly used in hospitalized patients without apparent reason, write the study authors, Kevin T. Shiley, Ebbing Lautenbach and Ingi Lee, all from the University of Pennsylvania School of Medicine. The recognition of what may be useful in developing interventions to reduce inappropriate use of antibiotics in the future.

Abiraterone acetate is a new pill to prolong the life of the treatment of advanced prostate cancer. Unlike traditional chemotherapy used in these situations, Abiraterone is generally very well tolerated, said Flaig.

The multi-center Phase III clinical trial of 1195 participants examined the effectiveness of the treatment of patients who had received prior chemotherapy with a combination of Abiraterone acetate and prednisone. When this process started, there are treatments that clearly prolonged survival at this late stage of prostate cancer.

Treatment continued until disease progression, there were adverse reactions, a new treatment was started or the patient withdrew from the study.